Literature DB >> 21415707

Epigenetic modifications of histone h4 in lung neuroendocrine tumors.

Faqian Li1, Bo Ye, Longsheng Hong, Haodong Xu, Michael C Fishbein.   

Abstract

Global profiling of histone changes in some human cancers demonstrated that loss of histone H4 acetylation at lysine16 (H4KA16) and trimethylation at lysine 20 (H4KM20) was a common hallmark of cancer. It is not clear whether these epigenetic changes also exist in neuroendocrine carcinomas. We semiquantitatively analyzed 32 cases of lung neuroendocrine tumors (LNETs) immunohistochemically stained with H4KA16, H4KM20, and Ki67 antibodies by calculating cumulative scores based on the sum of the product of nuclear stain intensity (1-3) and percentages of positive cells in each category. H4KA16 and H4KM20 levels were compared among typical carcinoid (TC, 11), atypical carcinoid (AC, 6), large cell neuroendocrine carcinoma (LCNEC, 8), and small cell lung cancer (SCLC, 7) and correlated with histologic types and Ki67 labeling. Data were presented as mean±standard error of the mean and statistically analyzed by 1-way analysis of variance and Holm-Sidak method. Normal bronchiolar epithelium had relatively uniform and strong +3 positivity of H4KM20 and H4KA16, which was considered as internal positive controls. This uniformity, however, was gradually lost from low to high grades of LNETs. Semiquantitative analysis revealed that there were significant differences in cumulative scores of H4KA16 (TC, 2.36±0.03; AC, 2.04±0.08; LCNEC, 1.58±0.07; SCLC 1.32±0.05) among LNETs. For H4KM20, significant differences were only observed between low grade (TC, 2.49±0.05 and AC, 2.24±0.09) and high grade (LCNEC, 1.58±0.10 and SCLC 1.68±0.11) LNETs, but not within low or high grade LNETs. The Ki67 cumulative scores (TC, 0.06±0.02; AC, 0.41±0.08; LCNEC, 1.29±0.09; SCLC 1.83±0.06) were inversely correlated with both cumulative H4KA16 and H4KM20 scores by Pearson correlation. We conclude that progressive loss of H4KA16 and H4KM20 from low to high grade LNETs reflects the degree of differentiation and proliferative activity. These histone modifications may serve as tumor biomarkers that may aid in diagnosis and prediction of clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21415707     DOI: 10.1097/PAI.0b013e3182108e2e

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  8 in total

1.  Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.

Authors:  Alessandra Fabbri; Mara Cossa; Angelica Sonzogni; Mauro Papotti; Luisella Righi; Gaia Gatti; Patrick Maisonneuve; Barbara Valeri; Ugo Pastorino; Giuseppe Pelosi
Journal:  Virchows Arch       Date:  2017-01-04       Impact factor: 4.064

2.  Correlation between histone acetylation and expression of Notch1 in human lung carcinoma and its possible role in combined small-cell lung carcinoma.

Authors:  Wael Abdo Hassan; Shin-Ichiro Takebayashi; Mohamed Osama Ali Abdalla; Kosuke Fujino; Shinji Kudoh; Yamoto Motooka; Yonosuke Sato; Yoshiki Naito; Koichi Higaki; Joeji Wakimoto; Seiji Okada; Mituyoshi Nakao; Yuichi Ishikawa; Takaaki Ito
Journal:  Lab Invest       Date:  2017-04-17       Impact factor: 5.662

Review 3.  Histone Modification on Parathyroid Tumors: A Review of Epigenetics.

Authors:  Luiz C Conti de Freitas; Rogerio M Castilho; Cristiane H Squarize
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

4.  Emerging role of linker histone variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation of H3K9 and H4K20.

Authors:  Athanasia Sepsa; Georgia Levidou; Antonis Gargalionis; Christos Adamopoulos; Anastasia Spyropoulou; Georgia Dalagiorgou; Irene Thymara; Efstathios Boviatsis; Marios S Themistocleous; Kalliopi Petraki; George Vrettakos; Vassilis Samaras; Athanassios Zisakis; Efstratios Patsouris; Christina Piperi; Penelope Korkolopoulou
Journal:  PLoS One       Date:  2015-01-20       Impact factor: 3.240

Review 5.  NETs: organ-related epigenetic derangements and potential clinical applications.

Authors:  Mauro Cives; Valeria Simone; Francesca Maria Rizzo; Franco Silvestris
Journal:  Oncotarget       Date:  2016-08-30

Review 6.  [Progress of Epigenetic Methylation in Lung Cancer Research].

Authors:  Shaowei Zhang; Zhiqiang Xue
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-09-20

Review 7.  Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know?

Authors:  Marco Volante; Ozgur Mete; Giuseppe Pelosi; Anja C Roden; Ernst Jan M Speel; Silvia Uccella
Journal:  Endocr Pathol       Date:  2021-02-27       Impact factor: 3.943

Review 8.  Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities.

Authors:  Miriam Grazia Ferrara; Alessio Stefani; Michele Simbolo; Sara Pilotto; Maurizio Martini; Filippo Lococo; Emanuele Vita; Marco Chiappetta; Alessandra Cancellieri; Ettore D'Argento; Rocco Trisolini; Guido Rindi; Aldo Scarpa; Stefano Margaritora; Michele Milella; Giampaolo Tortora; Emilio Bria
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.